Analysts expect that Teladoc, Inc. (NYSE:TDOC) will post sales of $67.50 million for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Teladoc’s earnings, with estimates ranging from $67.13 million to $67.80 million. Teladoc reported sales of $32.38 million during the same quarter last year, which would indicate a positive year over year growth rate of 108.5%. The firm is scheduled to announce its next quarterly earnings report on Thursday, October 26th.

On average, analysts expect that Teladoc will report full-year sales of $67.50 million for the current year, with estimates ranging from $230.50 million to $237.90 million. For the next fiscal year, analysts forecast that the company will post sales of $361.62 million per share, with estimates ranging from $350.56 million to $374.23 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Teladoc.

Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.02. Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The firm had revenue of $44.60 million for the quarter, compared to analysts’ expectations of $44.39 million. During the same period in the prior year, the company earned ($0.38) EPS. The firm’s quarterly revenue was up 68.3% on a year-over-year basis.

TDOC has been the topic of several research reports. Chardan Capital lifted their target price on Teladoc from $30.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, June 20th. William Blair reaffirmed an “outperform” rating on shares of Teladoc in a report on Tuesday, June 20th. Canaccord Genuity reaffirmed a “buy” rating and issued a $42.00 target price (up from $34.00) on shares of Teladoc in a report on Tuesday, June 20th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $27.00 target price on shares of Teladoc in a report on Monday, June 19th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $32.00 target price on shares of Teladoc in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $35.55.

In other Teladoc news, insider Adam C. Vandervoort sold 53,806 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the sale, the insider now directly owns 33,008 shares of the company’s stock, valued at $1,020,607.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.47% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Ameriprise Financial Inc. increased its stake in Teladoc by 125.7% during the first quarter. Ameriprise Financial Inc. now owns 131,493 shares of the health services provider’s stock worth $3,288,000 after acquiring an additional 73,231 shares during the last quarter. Driehaus Capital Management LLC bought a new stake in Teladoc during the first quarter worth approximately $6,411,000. Blair William & Co. IL bought a new stake in Teladoc during the first quarter worth approximately $218,000. Swiss National Bank increased its stake in Teladoc by 37.5% during the first quarter. Swiss National Bank now owns 56,800 shares of the health services provider’s stock worth $1,420,000 after acquiring an additional 15,500 shares during the last quarter. Finally, Riverbridge Partners LLC bought a new stake in Teladoc during the second quarter worth approximately $23,392,000.

Shares of Teladoc (TDOC) traded up 1.97% on Monday, hitting $33.65. The stock had a trading volume of 494,196 shares. The stock has a 50 day moving average of $31.87 and a 200-day moving average of $29.00. The stock’s market cap is $1.91 billion. Teladoc has a 12 month low of $14.00 and a 12 month high of $36.90.

WARNING: “$67.50 Million in Sales Expected for Teladoc, Inc. (TDOC) This Quarter” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/11/67-50-million-in-sales-expected-for-teladoc-inc-tdoc-this-quarter.html.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Get a free copy of the Zacks research report on Teladoc (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.